EA201500801A1 - Бензохинолоновые ингибиторы vmat2 - Google Patents

Бензохинолоновые ингибиторы vmat2

Info

Publication number
EA201500801A1
EA201500801A1 EA201500801A EA201500801A EA201500801A1 EA 201500801 A1 EA201500801 A1 EA 201500801A1 EA 201500801 A EA201500801 A EA 201500801A EA 201500801 A EA201500801 A EA 201500801A EA 201500801 A1 EA201500801 A1 EA 201500801A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vmat2
inhibitors
benzohinolone
methods
pharmaceutical compositions
Prior art date
Application number
EA201500801A
Other languages
English (en)
Inventor
Андреас Соммер
Чэнчжи Чжан
Original Assignee
Ауспекс Фармацетикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ауспекс Фармацетикалс, Инк. filed Critical Ауспекс Фармацетикалс, Инк.
Publication of EA201500801A1 publication Critical patent/EA201500801A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Настоящее изобретение относится к новым бензохинолоновым ингибиторам VMAT2, их фармацевтическим композициям и способам их применения
EA201500801A 2013-01-31 2014-01-28 Бензохинолоновые ингибиторы vmat2 EA201500801A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361758861P 2013-01-31 2013-01-31
PCT/US2014/013327 WO2014120654A1 (en) 2013-01-31 2014-01-28 Benzoquinolone inhibitors of vmat2

Publications (1)

Publication Number Publication Date
EA201500801A1 true EA201500801A1 (ru) 2016-01-29

Family

ID=51262872

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091397A EA202091397A1 (ru) 2013-01-31 2014-01-28 Бензохинолоновые ингибиторы vmat2
EA201500801A EA201500801A1 (ru) 2013-01-31 2014-01-28 Бензохинолоновые ингибиторы vmat2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202091397A EA202091397A1 (ru) 2013-01-31 2014-01-28 Бензохинолоновые ингибиторы vmat2

Country Status (11)

Country Link
US (4) US20160068526A1 (ru)
EP (3) EP2951178A4 (ru)
JP (3) JP2016506957A (ru)
AU (4) AU2014212586A1 (ru)
BR (1) BR112015017878A2 (ru)
CA (1) CA2899707A1 (ru)
EA (2) EA202091397A1 (ru)
HK (1) HK1219095A1 (ru)
IL (3) IL240146A0 (ru)
MX (2) MX2015009719A (ru)
WO (1) WO2014120654A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2930744A1 (en) 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
EP3398602A1 (en) * 2014-01-27 2018-11-07 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP4140483A1 (en) 2015-03-06 2023-03-01 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
RS65154B1 (sr) 2015-10-30 2024-02-29 Neurocrine Biosciences Inc Soli valbenazin dihidrohlorida i njihovi polimorfi
SI3394057T1 (sl) 2015-12-23 2022-06-30 Neurocrine Biosciences, Inc. Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
SG11201906883SA (en) 2017-01-27 2019-08-27 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
JP2020508337A (ja) 2017-02-27 2020-03-19 サンド・アクチエンゲゼルシヤフト バルベナジン塩の結晶形態
WO2019060322A2 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS AND KITS THEREOF
CN116492340A (zh) 2017-10-10 2023-07-28 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
TW202021585A (zh) 2018-08-15 2020-06-16 美商紐羅克里生物科學有限公司 用於特定vmat2抑制劑之投與之方法
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
KR20230160308A (ko) 2021-03-22 2023-11-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 Vmat2 억제제 및 사용 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) * 1958-07-15 Method for preparing same
US2830993A (en) 1958-04-15 Quinolizine derivatives
US3045021A (en) 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
KR20040068613A (ko) * 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE60001623T2 (de) * 1999-12-03 2003-12-18 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
EP2012833B1 (en) 2006-05-02 2014-10-29 The Trustees Of The University Of Pennsylvania Radiolabeled dihydrotrabenazine derivatives and their use as imaging agents
JP5290185B2 (ja) 2006-11-08 2013-09-18 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法
US8053578B2 (en) * 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
DK3061760T3 (en) 2008-09-18 2018-02-05 Auspex Pharmaceuticals Inc DEUTERATED BENZOQUINOLIZIN DERIVATIVES AS INHIBITORS OF VESICULAR MONOAMIN TRANSPORT 2
US20100113496A1 (en) * 2008-09-25 2010-05-06 Auspex Pharmaceuticals, Inc. Piperidine modulators of vmat2
US20120003330A1 (en) 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2

Also Published As

Publication number Publication date
AU2018203477A1 (en) 2018-05-31
EP3770159A1 (en) 2021-01-27
HK1219095A1 (zh) 2017-03-24
US20200165240A1 (en) 2020-05-28
CA2899707A1 (en) 2014-08-07
US20210355120A1 (en) 2021-11-18
AU2021201629A1 (en) 2021-04-08
MX2020001756A (es) 2020-07-28
IL240146A0 (en) 2015-09-24
AU2019268062A1 (en) 2019-12-12
BR112015017878A2 (pt) 2017-07-11
AU2014212586A1 (en) 2015-08-06
JP2019048829A (ja) 2019-03-28
JP2016506957A (ja) 2016-03-07
EP2951178A4 (en) 2016-07-06
EP3421469A1 (en) 2019-01-02
JP2021100941A (ja) 2021-07-08
IL267154A (en) 2019-08-29
WO2014120654A1 (en) 2014-08-07
EP2951178A1 (en) 2015-12-09
IL279682A (en) 2021-03-01
MX2015009719A (es) 2016-08-08
US20180208592A1 (en) 2018-07-26
EA202091397A1 (ru) 2020-09-04
US20160068526A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201691582A1 (ru) Новые фармацевтические препараты
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
EA201591137A1 (ru) Ингибиторы mk2 и их применения
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201591961A1 (ru) Ингибиторы акк и их применение
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
EA201692269A1 (ru) Новые композиции, их использование и способы получения
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA201591962A1 (ru) Ингибиторы акк и их применение
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана